Chiasma Inc. (NASDAQ:CHMA) dropped 7.8% during trading on Tuesday . The company traded as low as $2.71 and last traded at $2.71, with a volume of 112,894 shares trading hands. The stock had previously closed at $2.94.

CHMA has been the topic of a number of analyst reports. Cowen and Company reaffirmed a “hold” rating on shares of Chiasma in a research note on Friday, May 13th. Zacks Investment Research lowered shares of Chiasma from a “hold” rating to a “sell” rating in a research note on Monday, April 25th. Oppenheimer Holdings Inc. reaffirmed an “outperform” rating and issued a $9.00 price objective (down from $43.00) on shares of Chiasma in a research note on Monday, April 18th. Barclays PLC lowered shares of Chiasma from an “overweight” rating to an “equal weight” rating and reduced their price objective for the company from $40.00 to $5.50 in a research note on Monday, April 25th. Finally, William Blair lowered shares of Chiasma from an “outperform” rating to a “market perform” rating in a research note on Monday, April 18th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and one has issued a buy rating to the company. Chiasma presently has a consensus rating of “Hold” and an average price target of $14.63.

The stock’s 50-day moving average price is $2.81 and its 200-day moving average price is $5.74. The company’s market cap is $65.86 million.

Chiasma (NASDAQ:CHMA) last announced its earnings results on Wednesday, August 10th. The company reported ($1.10) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.63) by $0.47. Analysts expect that Chiasma Inc. will post ($2.84) earnings per share for the current fiscal year.

Chiasma, Inc is a biopharmaceutical company. The Company is engaged in developing and commercializing oral forms of therapies that are available only by injection. Using its Transient Permeability Enhancer (TPE) technology platform, the Company is developing oral therapies. The Company has completed a Phase III clinical trial of its TPE platform-based product candidate, oral octreotide capsules (trade named as MYCAPSSA) for the treatment of acromegaly, a condition that results in the body’s production of excess growth hormone.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.